palonesetron

DRUG2 trials

Sponsors

Eisai Inc., Instituto Brasileiro de Controle do Cancer

Conditions

Nausea Post ChemotherapyPatients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

Phase 2

A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC)

CompletedNCT01054456

Eisai Inc.Patients With Confirmed Malignant Disease to Receive Low Emetogenic Chemotherapy (LEC) or Who Experienced at Least Nausea and Vomiting During Last Cycle of LEC

Start: 2009-10-27End: 2010-12-08Updated: 2020-12-23

Efficacy of Olanzapine, Netupitant and Palonosetron in Controlling Nausea and Vomiting Associated With Highly Emetogenic Chemotherapy in Patients With Breast Cancer

CompletedNCT04669132

Instituto Brasileiro de Controle do CancerNausea Post Chemotherapy

Start: 2020-12-17End: 2022-01-17Updated: 2022-02-23

Related Papers

Efficacy of olanzapine, netupitant, and palonosetron in controlling nausea and vomiting associated with highly emetogenic chemotherapy in patients with breast cancer (OLNEPA).

Journal of Clinical Oncology2022-06-01